All News

The company says addressing the issues raised in the CRL could take years.

The list prevents the import of ingredients from potentially dangerous facilities.

Regeneron’s Phase III trials show promising results for new antibody treatments, offering rapid and lasting relief from cat and birch allergies.

Servier's acquisition of KER-0193 marks a pivotal step in developing innovative treatments for Fragile X syndrome, enhancing its neurology pipeline.

Gilead Sciences partners with PEPFAR to enhance access to Lenacapavir for HIV prevention, aiming to support over 2 million people in resource-limited countries.

BioNTech's BNT323 shows promise in slowing breast cancer progression, boosting shares and paving the way for new treatment options.

WHO designates GLP-1 medications for diabetes as essential, aiming to improve access and affordability for patients worldwide.

In today’s Pharmaceutical Executive Daily, we will recap the top stories of the week, exploring the current state of the GLP-1 market, review major pharmaceutical layoffs shaping 2025, and cover Pfizer’s response to political pressure on COVID-19 vaccine safety evidence.

Radiance Biopharma partners with Novatim to advance RB-601, a promising bispecific nanobody ADC targeting key cancer drivers for solid tumors.

In today’s Pharmaceutical Executive Daily, we cover political pressure on Moderna and Novavax to release COVID-19 vaccine evidence, a deep dive into the evolving GLP-1 market, and Sanofi’s share decline following disappointing Phase III results for Amlitelimab.

The deal gives Avadel global rights to develop and market valiloxybate for narcolepsy and idiopathic hypersomnia, with a once-at-bedtime, sodium-free formulation designed to improve patient convenience and outcomes.

Sanofi's stock plummets over 10% as Amlitelimab's Phase III trial results raise concerns about the company's future pipeline and Dupixent's patent expiration.

These drugs have quickly become household names due to their popularity as weight loss medications.

SeqOne's acquisition of Congenica enhances its AI-driven genomic solutions, expanding global reach and transforming genetic data analysis for personalized medicine.

Novo Nordisk reveals Wegovy's 57% greater risk reduction for heart attack and stroke compared to Tirzepatide in obese patients at ESC Congress.

The two companies issued statements detailing the number of studies about the vaccines’ impact.

As more companies announce layoffs and other restructuring plans, industry experts are asking what will happen next.

Pharmaceutical Executive Daily highlights Pfizer's defense of vaccine data integrity, insights on GLP-1 investments, and Novartis' $5.2 billion acquisition of Argo Biopharmaceuticals.

The company pointed the President to existing published research and pledged to post more to its site.

Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using War-Lock technology, enhancing treatment options.

Argo Biopharmaceuticals partners with Novartis to advance innovative siRNA therapies for cardiovascular diseases, enhancing treatment options and patient outcomes.

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their unique OdyssION drug discovery platform.

The feature will be available on the company’s platform Nuro.

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and safety in care.

Wayrilz is the first Bruton’s tyrosine kinase inhibitor to be approved for adults with persistent or chronic immune thrombocytopenia who have not responded adequately to prior therapy.

Johnson and Johnson halts Nipocalimab's development for rheumatoid arthritis after Phase 2a trial shows no significant benefits over existing therapies.

The blood purification technology is used for the treatment of severe treatment-refectory systematic lupus erythematosus (SLE).

Lilly has temporarily halted UK shipments of Mounjaro until Sept. 1, when new list prices take effect.

Outlook Therapeutics faces FDA hurdles for Lytenava's approval in wet AMD, seeking clarity on efficacy requirements while expanding globally.

A monthly roundup of business and people news in the pharmaceutical industry.